The pathophysiology of thrombocytopenia in the syndrome of thrombocytopenia with absent radii (TAR) is not yet understood. We examined thrombopoietin (TPO) serum levels and the in vitro reactivity of platelets to TPO in five patients affected with TAR syndrome. We found elevated TPO serum levels in all patients tested, excluding a TPO production defect as cause for thrombocytopenia in TAR syndrome. In addition, we found similar expression of the TPO receptor c-Mpl on the surface of platelets from TAR patients (5 of 5) and a similar molecular weight of the receptor as compared with healthy controls (4 of 4). Platelet response to adenosine diphosphate or thrombin receptor agonist peptide SFLLRN (TRAP) was normal in TAR patients. However, in contrast to results with healthy controls we could show absence of in vitro reactivity of platelets from TAR patients to recombinant TPO as measured by testing TPO synergism to adenine diphosphate and TRAP in platelet activation. TPO induced tyrosine phosphorylation of platelet proteins was completely absent (3 of 4) or markedly decreased (1 of 4). Our results indicate that defective megakaryocytogenesis in TAR syndrome is not caused by a defect in TPO production but a lack of response to TPO in the signal transduction pathway of c-Mpl.

© 1997 by The American Society of Hematology.
thrombocytopenia and bilateral radial aplasia. Although first described in 1929, it was defined as a syndrome by Hall et al in 1969. TAR seems to be inherited in an autosomal recessive manner. The pathogenesis of TAR is poorly understood. Bone marrow aspirates from TAR patients show either decreased or absent megakaryocytopenies, indicating that the thrombocytopenia is caused by a defective platelet production.

There are inconsistent reports about "thrombopoietin like" activity and megakaryocyte colony-stimulating activity (Mega-CSA) in the serum of TAR patients. The presence of colony forming units for megakaryocytes (CFU-Mega) in the bone marrow of TAR patients is controversial, too. Whereas some investigators did not find any growth of megakaryocytic colonies from the bone marrow of TAR patients, de Alarcon et al showed normal CFU Mega counts with an abnormal colony morphology. Cells in these colonies were smaller, and the number of cells per colony was much higher than in normal CFU-Mega-derived colonies.

Platelet function seems to be normal in TAR patients, but there are also some reports about abnormal platelet morphology and function.

In 1994 several groups purified and cloned a new hematopoietic factor: thrombopoietin (TPO). Since then, this cytokine has been shown to be the major regulator of megakaryocytopenesis and thrombocytopenesis. Investigations of the in vitro and in vivo effects of TPO showed that it acts as a Mega-CSF as well as a megakaryocyte maturation factor and a positive regulator of platelet production in vivo. The receptor for TPO, the product of the proto-oncogene c-mpl, is expressed in the megakaryocytic lineage from progenitor cells to platelets. c-mpl, a cellular homologue of the v-mpl oncogene, was found to be a member of the cytokine receptor superfamily that share common signal transduction pathways. Binding of the ligand leads to tyrosine phosphorylation of some cellular proteins in cell lines and platelets.

Our aim was to elucidate a possible relationship between the TAR-related thrombocytopenia and the TPO-c-Mpl system. Here we present the first report about TPO serum levels in TAR patients and about the in vitro reactivity of platelets from TAR patients to recombinant human (rh) TPO. Our results indicate that defective megakaryocytopenesis thrombocytopenesis in TAR syndrome is
not caused by a defect in TPO production but by a lack of response to TPO in the signal transduction of c-Mpl.

MATERIALS AND METHODS

Patients. We examined samples from five unrelated children with TAR syndrome. The patients' characteristics are described in detail in Table 1. It is important to note that four of the patients required platelet transfusions.

Patient 1 was a 3-year-old girl with bilateral absent radii and hypoplastic, curved ulna and with platelet counts usually about 50,000 /µL. She needed three platelet transfusions during the first year of life. Aside from this, a clinically irrelevant ventricle septum defect (VSD) was stated.

Patient 2 was a 3-year-old girl with bilateral absent radii and short ulna with platelet counts usually approximately 20,000 /µL. During infections she required platelet transfusions because of bleedings from nose and mouth.

Patient 3 was a 6-week-old boy at first examination. He showed bilateral absent radii, a short ulna right, an ulna aplasia lef, and a bilateral hip Úranslocation. Because of a severe thrombocytopenia he needed platelet transfusions twice a month for the first 3 months of life. Platelet counts were between 25,000 at the time of the first examination and 72,000 at the age of 10 months.

Patient 4 was a 6-month-old baby girl. Bilateral absent radii and

From the Department of Pediatric Hematology and Oncology, Medical Sch 001 Haim oy'e r, German and A ~ngen Inc, Thotisand öaks. CA. The first ~vo autllors contributed equally' to this work.

SL£hlflitted April 1, 1996; accepted March 6, 1997.

St'pported by Grant No. We 942/5-1 from Deutsche Forschungs gemeinschaft (DFÜ).

Address reprint requests to Karl Weite, MD, PhD, Abt Pädia trische Häinatologie und Onkologie, Medizuiische Hochschule Hannover, D-30623 Hannover, Germany.
short ulnae, as well as a severe thrombocytopenia, lead to the diagnosis of TAR. Megakaryocytes were completely absent in a bone marrow sample from the first week of life. This sample was used for the clonogenic assay presented here.

Patient 5, a 7-year old girl, has been described in an earlier publication by us.6 She showed absent radii and short ulnae—thumb hypoplasia and shoulder-girdle involvement. In addition, a VSD was stated. In contrast with other reports about TAR-syndrome, bleeding problems continued up to now. For instance, in the last year she had problems with petechiae and bleeding with platelet counts between 10,000 and 20,000/µL.

Matenais. rhTPO was provided by Dr A. Shimosaka Kinn Brewery (Tokyo, Japan). rh granulocyte colony-stimulating factor (G-CSF) and rh stern cell factor (SCF) were provided by Amgen (Thousand Oaks, CA). rh granulocyte-macrophage colony-stimulating factor (GM-CSF) and rh interleukin-3 (IL-3) were a gift from Behringwerke (Marburg, Germany), rh erythropoietin (EPO) was obtained from Boehringer Mannheim (Mannheim Germany). Aden osine diphosphate (ADP), prostaglandin El (PGEl), acetyl salicylic acid, apyrase (type VIII), and bovine serum albumine (BSA) were purchased from Sigma (Deisenhofen, Germany). The thrombin receptor agonist

\[ \text{Table 1. TAR Patients} \]

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Sex</th>
<th>Absent Radii</th>
<th>Requirement of Platelet Transfusions</th>
<th>Age</th>
<th>WBC (µL⁻¹)</th>
<th>Hgb (g/dL)</th>
<th>Pt (µL⁻¹)</th>
<th>Tests Performed*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>+</td>
<td>-</td>
<td>2 yr 6 mo</td>
<td>8,100</td>
<td>11.7</td>
<td>57,000</td>
<td>1, 2, 3, 4, 5</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>+</td>
<td>+</td>
<td>3 yr 7 mo</td>
<td>6,700</td>
<td>12.1</td>
<td>87,000</td>
<td>1, 2, 3, 4, 5</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>+</td>
<td>-</td>
<td>1 yr 11 mo</td>
<td>15,000</td>
<td>8.6</td>
<td>28,000</td>
<td>1, 3, 4, 5</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>+</td>
<td>-</td>
<td>2 yr 9 mo</td>
<td>ND</td>
<td>ND</td>
<td>31,000</td>
<td>1, 2, 3, 4, 6</td>
</tr>
<tr>
<td>5f</td>
<td>F</td>
<td>+</td>
<td>-</td>
<td>6 wk</td>
<td>10,800</td>
<td>8.0</td>
<td>26,000</td>
<td>1, 2, 3, 4, 5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10 mo</td>
<td>11,900</td>
<td>13.8</td>
<td>72,000</td>
<td>1, 2, 3, 4, 6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8 d</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>1, 2, 3, 5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6 mo</td>
<td>27,000</td>
<td>8.7</td>
<td>10,000</td>
<td>1, 2, 3, 5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5 yr 11 mo</td>
<td>12,000</td>
<td>10.7</td>
<td>12,000</td>
<td>1, 2, 3, 5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7 yr 8 mo</td>
<td>8,400</td>
<td>8.4</td>
<td>12,000</td>
<td>1, 2, 3, 4, 5</td>
</tr>
</tbody>
</table>

**Abbreviations**: WBC, white blood count; Hgb, Hemoglobin; Pt, platelets; ND, not determined.

* Code for the different examinations: 1, TPO serum level; 2, IL-11, IL-6, LIF level; 3, c-Mpl (flow cytometry); 4, c-Mpl (Western-blotting); 5, TPO reactivity (flow cytometry); 6, TPO reactivity (Tyrosine phosphorylation); 7, CFU-mega.

† This patient has been described in an earlier abstract.
peptide (serine-phenylalanine-leucine-ileucine-arginine-asparagine, TRAP) was purchased from Bachem (Heidelberg Germany). Monodonal anti bodies against CD62 and CD41, as well as the IgG isotype control were purchased from Immunotech (Hamburg, Germany), the monodonal antibody against human c-Kit was obtained from Genzyme (Rüsselsheim Germany), the horse-radish peroxidase (HRP)-conjugated recombinant antiphosphotyrosine anti body RC20 was purchased from Transduction Laboratories (Lexington, KY). The reagents for the enhanced chemiluminescence (ECL) and the 3H-thymidine were obtained from Amersham (Braunschweig, Germany). Ccl culture media and fetal calf serum were purchased from Life Technologies (Eggenstein, Germany).

TPO serum levels. TPO serum levels were measured in a bioassay using the murine IL-3-dependent 32D (clone 23) cells24 transfected with the human c-mpl. Serum samples were preabsorbed with the parental 32D (clone 23) cells to remove complement activity. For the assay, 32D/Mpl cells were washed free of IL-3 and plated (3,000 cells, 100 µL total volume per well) in flat-bottomed 96-well plates (Nunc, Wiesbaden, Germany) in RPMI 1640 medium supplemented with 5% heat-inactivated fetal calf serum in 100 µL serial dilutions of test sera in assay medium. After 72 hours, the microtiter cultures were pulsed with 3H-thymidine (0.5 Ci/well, specific activity 5 Ci/mmol) for another 4 hours. The radioactive uptake was determined in a liquid scintillation counter. Serial dilutions of rhTPO in preabsorbed human serum were used as standards.

the concentrations of the samples were calculated from the standard curve by probit analysis. The sensitivity of the assay was 100 pg/mL.

Serum levels of IL-6, IL-11, and interleukin inhibitor factor (LIF). Serum levels of IL-6 and IL-11 were measured in commercially available enzyme-linked immunosorbent assay (ELISA) systems (Quantikine, R&D systems, Abingdon, UK). Detection limits were 8 pg/mL for IL 6 and 30 pg/mL for IL 11. Serum levels of LIF were measured in a sandwich ELISA. Briefly, a monodonal antibody (MoAb) against LIF served as capturin a polyclonal rabbit antiserum was used for detection. The detection limit of this assay was 30 pg/mL.

Assay for CFUs. Bone marrow mononuclear cells (BM-MNCs, 105) obtained by density gradient centrifugation with Ficoll were cultured in duplicates in 1 mL aliquots in a semi solid medium containing 0.7% methyl cellulose (vlethocel A4C WAK Chemie Bad Homburo Germany), 30% human fresh frozen plasma (Blood Bank Medical School Hannover Germany), 0.5 x 10-9 mol/L 2 mercaptoethanol in Iscove’s modified Dulbecco’s medium in 35- mm culture dishes. Hematopoietic growth factors were added as specified in the Results section. The cultures were incubated at 370C in an atmosphere of 5% CO2 and 100% humidity for 14 days. After this time, colonies were analyzed and counted in an inversion micro scope. Megakaryocytic colonies were picked, spinne on sudes, and May-Grünwald/Giemsa stained for verifying the megakaryocytic morphology of the cells.

Costimulation of T-cells with TPO. Blood of healthy volun teers or TAR patients was obtained from an antecubital vein through a 19-gauge needle with only a light tourniquet into a plastic syringe containing trisodium citrate (10 mmol/L final concentration). Stimulation experiments were
started within 15 minutes after blood collection. Experiments were usually performed with whole blood, and in some cases (platelet counts < 50,000/µL) we used platelet-rich plasma (PRP). For preparing PRP, whole blood was centrifuged at 200g for 20 minutes and the supematant PRP was removed. All incubations were done at 370C. Five to 10 µL aliquots of blood or PRP containing 2 X 105 to 2 x 106 platelets were added to polystyrene tubes containing 60 µL of phosphate-buffered sahne (PBS; 130 mmol/L NaCl, 10 mmol/L sodium phosphate, pH 7.5) with various concentrations of rhTPO (20 ng/mL, unless indicated otherwise). After a preincubation of 5 minutes, the platelet activators ADP (final concentration 50 µmol/L) or TRAP26 (final concentration 5 µmol/L) were added. The stimulation was stopped by addition of 1 mL of a solution of 1 % formaldehyde in PBS. Unstimulated platelets serving as a negative control were fixed immediately after blood collection or preparation of PRP, respectively. The samples were stored for 30 minutes on ice before they were stained for flow cytometric analysis.

Flow cytometry. Fluorescein isothiocyanate (FITC)-conjugated MoAb anti P-selectin (CD62; clone CLB-Thromb/6) as an activa tion-dependent antibody and phycoerythrine (PE)-conjugated anti gplIbIIIa (CD41; clone P2) as a pan-platelet marker were used for determination of platelet activation. FITC- and PE-labeled isotype control antibodies (Immunotech, Hamburg, Germany) were used as control. Fixed platelets were pelleted (5 minutes, 2,00g), washed two times in FACS-buffer (PBS supplemented with 0.1 % BSA and 0.1 % sodium azide and then resuspended in 40 µL of a diluted human Ig solution (10 mg/mL GammaGard; Baxter, Unterschleißheim, Germany) for blocking the Fc-receptors. After a short preincubation 10 µL of each antibody solution was added followed by a 20-minute incubation on ice. To determine the c-Mpl expression on patients’ platelets we used an anti-c-Mpl MoAb (vi 1.17 Genzyme): Platelets were fixed and preincubated with human Ig as described before. Cells were incubated with the M 1 antibody (10 µL in the Ig-solution) or a nonspecific isotype control antibody for 30 minutes on ice. Cells were washed in FACS-buffer and then incubated with FITC-conjugated rabbit antimouse Ig (Dako, Glostrup, Denmark) according to manufacturer’s instructions.

After staining, platelets were washed two times in FACS-buffer and analyzed on a FACScan flow cytometer (Becton-Dickinson). FITC –uorescence was detected with a 530/30 nm and PE fluorescence was detected with a 585/42 nm band pass filter. Light scatter and fluorescence data were obtained with gain settings in the logarithmic mode. Platelets were distinguished from other cells, debris, and machine noise” on the basis of their scatter profile. In some cases a fluorescence threshold was set to analyze only those blood cells that had bound the PE-conjugated anti-CD4 1 antibody.

Platelet preparation for gel electrophoresis and immunoprecipitation. PRP from whole blood was prepared as described above. PRP was incubated with acetyl salicylic acid (2 mmol/L) for 30
minutes at room temperature. Then PGE 1 (1 µmol/L) was added from a 1-mmol/L stock solution in absolute ethanol. A soft pellet was obtained by centrifugation of the PRP at 800g for 10 minutes. The pellet was resuspended in a modified HEPES-Tyrode buffer as recently described21 also containing apyrase (2 U/mL) to avoid stimulation of platelets by ADP and washed only once to minimize additional physical stress. The platelets were resuspended in the same buffer, which was recalcified containing 1 mmol/L CaCl2 at 370C.

Gel electrophoresis and Western blotting. The stimulation of platelets was terminated by adding an equal volume of 2x-concentrated sample buffer (10% glycerol, 1% sodium dodecyl sulfate [SDS], 5% 2-mercapto-ethanol, 50 mmol/L Tris-HCl pH 6.8, 10 mmol/L EGTA and 1 mmol/L sodium orthovanadate and 0.002% bromophenol blue). SDS-gel electrophoresis of platelet proteins was run on a 7.5% polyacrylamide gel after boiling the samples for 5 minutes.

The proteins were transferred onto a nitrocellulose membrane by semidyry Western blotting with a buffer containing 50 mmol/L Tris, 40 mmol/L glycine, 0.04% SDS, and 17.5% methanol for 1.5 hours at room temperature.

For blocking unoccupied binding sites the membrane was incubated in PBS-T (0.1% Tween 20 in PBS) with 1% BSA (blocking buffer). For the detection of phosphorysine or c-Mpl the membrane was incubated in blocking buffer with MoAb against c-Mpl (done M 1:1,000) or with HRP-conjugated recombinant MoAb against phosphorysine (RC2O, 1:2,500) overnight at 40C with gentle motion.

In the case of c-Mpl the MoAb was removed and the membrane was washed four times with PBS-T and incubated with HRP-conjugated secondary antibody (diluted 1:1,000 in PBS-T) for 1 hour at room temperature with gentle motion.

After washing the blots in PBS-T four times the antibody reactions were detected by chemiluminescence with the ECL reagents (Amer sham) according to the manufacturer’s instructions.

Immunoprecipitation. The platelet stimulation was terminated by adding an equal amount of lysis buffer [15 mmol/L HEPES, 150 mmol/L NaCl, 1 mmol/L phenylmethylsulfonyl fluoride (PVISF), 10 mmol/L EGTA, 1 mmol/L sodium orthovanadate 0.8 mg/mL leupeptin, 2% (vol/vol) Triton X-100, pH 7.4]. The samples were incubated for 20 to 30 minutes on ice and afterwards the debris was pelleted at 10,000g for 20 minutes at 40C. The supernatant was removed and precleared by adding 50 µL of 50% slurry of protein A-agarose-beads (Upstate Biotechnology, New York, NY) for 1 hour in an orbital shaker at 40C. The beads were centrifuged at 10,000g for 10 minutes, and the supernatant was transferred into a new tube. The MoAb against human c-Mpl (Genzyme) was added and incubated for 4 hours or overnight in an orbital shaker at 40C. Then the complex was captured adding protein A-agarose-beads (50 µL of 50% slurry) for another 2 to 4 hours.
The immune complexes were washed three times with ice-cooled immunoprecipitation-buffer (50 mmol/L Tris-Cl: pH 7.4; 1% Noni det P-40; 150 mmol/L NaCT; 1 mmol/L EGTA; 1 nmol/L PMSF; 1 µg/mL of the protease inhibitors aprotinin, leupeptin, and pep statin; 1 mmol/L sodium vanadate; and 1 mmol/L sodium fluoride). Resuspended in an equal volume of 2X-sample buffer, and detected by Western blotting after SDS-PAGE.

RESULTS

Serum levels of TPO, IL-6, IL-11, and LIF. In healthy control persons TPO serum levels normally were not detectable in the bioassay (detection limit: 100 pg/mL). In contrast, TPO serum levels were above the detection limit in all serum samples from TAR patients with the exception of the first serum sample of patient 2 (Table 2).

Levels of other cytokines known to influence thrombopoiesis were evaluated in the sera of the TAR patients. Serum levels of IL-6 and LIF were undetectable in all cases (detection limits 8 respectively 30 pg/mL). In contrast IL-11 serum levels were elevated above 300 pg/mL in three out of five TAR patients (Table 2).

CFU-mega assay. Colony forming assays were performed with bone marrow cells of one patient only (no. 4). We had no consent of the other patients' parents for bone marrow evaluation and there was no clinical need for bone marrow evaluation. In the patient tested, no megakaryocytic colonies were observed after stimulation of BM-MNC with rhTPO (10 ng/mL; Table 3). For comparison, in healthy controls the median number of megakaryocytic colonies was 11 (n = 12). In contrast, the numbers of CFU-GM and BFU E colonies grown from the TAR patients' bone marrow were elevated as compared with healthy controls (Table 3).

Expression of c-Mpl on platelets. Expression of the TPO receptor c-Mpl on platelets was determined by flow cytometry in all patients and by Western blotting in four out of five TAR patients (patients no. 1, 2, 3, and 5) (Fig 1). Because the receptor is presumably expressed on all cells of the megakaryocytic lineage, we used platelets as an example for c-Mpl expression in TAR patients. We could show a specific binding of a MoAb against the c-Mpl on platelets of all patients tested. Fluorescence intensity after staining with the anti-c-Mpl in platelets from the TAR patients was in the range of normal controls (Fig 1A). The molecular weight of

The TAR syndrome is a rare congenital disorder characterized by the absence of limbs on both arms and severe thrombocytopenia during the first years of life. Recent studies showed that the
thrombocytopenia seen in TAR patients is caused by a defect in the megakaryocytopenia/thrombocytopenia. Different possible mechanisms for this bone marrow failure can be postulated: (1) absence of humoral or cellular stimulators of megakaryocytopenia, (2) absence of megakaryocyte progenitor cells, (3) cellular defects in megakaryocyte precursors (e.g., receptor defects), or (4) presence of humoral or cellular inhibitors of megakaryopoiesis.

There are controversial reports concerning Mega-CSA or "TPO-like" activities in the sera of TAR patients. Our group and others found high Mega-CSA in the sera of TAR patients. However, de Alarcón et al. reported Mega-CSA and "TPO-like" activities in the serum of one TAR patient, which were within the range of normal and below the high levels seen in amegakaryocytic subjects. Miehalevitz et al. even found an inhibitory effect of plasma of one TAR patient on the growth of multipotent and megakaryocytic progenitors. After the discovery of TPO and its receptor c-Mpl we were able to measure the activity of this major humoral regulator of megakaryocytopenia and thrombocytopenia in the sera of TAR patients. We found elevated levels of bioactive TPO in sera from all TAR patients tested, excluding a TPO production defect as the cause of thrombocytopenia in TAR syndrome. It is a common phenomenon that

FIG 1. Expression of c-Mpl on platelets from TAR patients. IA1 c-Mpl expression on the surface of platelets was measured by flow cytometry see Materials and Methods. Gray isotype control; black, anti c-Mpl. IB Detection of c-Mpl in platelet lysates after immunoprecipitation and Western blot analysis with anti-c-Mpl antibody. Chemoluminescence detection, See Materials and Methods. Lane 1, healthy donor; lane 2, TAR patient no. 1.

lineage specific hematopoietic growth factors are inversely regulated with the number of
corresponding mature cells in peripheral blood. This has been shown for G-CSF,28 EPO,29,30. and TPO31,32 and was found to be the case in a number of congenital cytopenias as the severe congenital neutropenia, also,33 The first determination of TPO serum levels of patient 2 yielded no elevated level of this cytokine. We have no explanation of that discrepancy. However, the first determination has been made with a relatively old serum sample and we cannot exclude a loss of activity during inappropriate storage. On the other hand, variations of TPO levels in TAR syndrome might be the reason for differences in former reports.

The presence of colony forming units megakaryocyte (CFU-Mega) in the bone marrow of TAR patients is another point of controversy in the literature. Whereas most groups, like us, did not find any growth of megakaryocytic colonies from TAR patients,4–6 de Alarcon et al7 showed normal CFU.

The presence of colony forming units megakaryocyte (CFU-Mega) in the bone marrow of TAR patients is another point of controversy in the literature. Whereas most groups, like us, did not find any growth of megakaryocytic colonies from TAR patients.4–6 de Alarcon et al7 showed normal CFU.

Table 2. Levels of TPO, IL-6, IL-11, and LIF in Serum of TAR Patients

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age</th>
<th>Platelet Count</th>
<th>TPO (pg/mL)</th>
<th>IL-6 (pg/mL)</th>
<th>IL-11 (pg/mL)</th>
<th>LIF (pg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2 yr 6 mo</td>
<td>57,000</td>
<td>&gt;1,000</td>
<td>&lt;8</td>
<td>&lt;30</td>
<td>&lt;30</td>
</tr>
<tr>
<td>2</td>
<td>1 yr 11 mo</td>
<td>28,000</td>
<td>&lt;100</td>
<td>nd</td>
<td>nd</td>
<td>nd</td>
</tr>
<tr>
<td>3</td>
<td>2 yr 9 mo</td>
<td>31,000</td>
<td>&gt;1,000</td>
<td>&lt;8</td>
<td>380</td>
<td>&lt;30</td>
</tr>
<tr>
<td>4</td>
<td>6 wk</td>
<td>25,000</td>
<td>&gt;1,000</td>
<td>&lt;8</td>
<td>&lt;30</td>
<td>&lt;30</td>
</tr>
<tr>
<td>5</td>
<td>10 mo</td>
<td>72,000</td>
<td>500-1,000</td>
<td>&lt;8</td>
<td>&lt;300*</td>
<td>&lt;30</td>
</tr>
<tr>
<td>6</td>
<td>6 mo</td>
<td>10,000</td>
<td>500-1,000</td>
<td>&lt;8</td>
<td>660</td>
<td>&lt;30</td>
</tr>
<tr>
<td>7</td>
<td>6 yr 11 mo</td>
<td>12,000</td>
<td>500-1,000</td>
<td>&lt;8</td>
<td>&lt;30</td>
<td>&lt;30</td>
</tr>
<tr>
<td>8</td>
<td>7 yr 8 mo</td>
<td>34,000</td>
<td>100-500</td>
<td>&lt;8</td>
<td>330</td>
<td>&lt;30</td>
</tr>
</tbody>
</table>

Normal range: <100 (n = 36); <81; <301; <30 (n = 50)

Abbreviations: nd, not determined.

* Because of the little volume of the serum sample of patient 4 we had to dilute the serum for IL-11 determination.
† Information provided by the manufacturer of the ELISA system.

The concentration of c-Mpl on the platelets from the TAR patients was found to be 86 kD as determined by SDS-PAGE and was not different from that of healthy controls (Fig 1B).

Costiruulotjou of platelets with TPO. TPO synergizes with ADP or thrombin receptor agonists to activate platelets as measured by increased expression of P-selectin (CD62P).2 We used this fact for in vitro testing of TPO reactivity of platelets from TAR patients. (CD62P).27 served as an activation-dependent marker. Using this method, platelets from normal individuals showed a synergism of rhTPO (5 - 10 ng/mL) with the platelet activators ADP and TRAP. Although there was a great variety in the reactivity of platelets tu the activators ADP and TRAP, platelets from all TAR patients showed reactivity in the range of normal controls (Fig 2 and Table 4). However, we could not detect the expected synergism of these platelet activators with rhTPO up to concentrations of 1 μg/mL in these patients. The results of one representative experiment are shown in Fig 2. To quantitate the synergistic effect of TPO on platelet activation we calculated the ratio between the amount of CD62P-positive cells after TPO costimulation (with ADP or TRAP) and the amount of CD62P-positive cells after control stimulation without TPO (Table 4). TPO preincubation (20 ng/mL) lead tu a 1.6-fold (~0.3) enhancement of ADP stimulation (50 μmol/L) or 1.4-fold (~0.3) enhancement of TRAP stimulation (5 μmol/L) in platelets of normal individuals (n = 6). In contrast, TPO stimulation indices in TAR patients were

1.0 0.1 for ADP and 1.0 0.2 for TRAP, respectively

(Table 4).
na/ transducer of c-Mpl after TPO binding. Because platelets express e-Mpl they are used as a mode for investigating signal transduction pathways of TPO. c-Mpl is a member of the cytokine receptor superfamily, which leads to tyrosine phosphorylation of cellular proteins.

We could show that stimulation of platelets with high concentrations of rhTPO for 5 minutes induced phosphorylation of several proteins, especially at 86 kD and higher (Fig 3). Stimulation with only 50 ng/mL rhTPO lead to phosphorylation of a 110-kD protein (data not shown). In Contrast, platelets from three out of four TAR patients (no. 1, 2, and 5) incubated with rhTPO concentrations up to 12 µg/mL showed no difference in tyrosine phosphorylation as compared with unstimulated cells (Fig 3), one other patient (no. 3) showed a weak phosphorylation of the 110-kD protein only after stimulation with rhTPO concentrations higher than 5 µg/mL.

**DISCUSSION**

Mega counts with an abnormal colony morphology. In these colonies cells were smaller and the number of cells per colony was much higher than in normal CFU-Mega derived colonies. In addition to the patient we tested earlier,6 we were able to test the presence of CFU-Mega in the bone marrow From only one TAR patient, a newborn baby-gin whose bone marrow was aspirated for diagnostic purposes.
We could not detect any megakaryocyte colony growth after stimulation with TPO, indicating that megakaryocyte development is markedly impaired. However, more patients need to be tested to make a final statement concerning megakaryocyte colony growth in vitro. In contrast, the numbers of non-megakaryocytic colonies (CFU-GM and BFU-E) stimulated by other growth factors (G-CSF, GM-CSF, IL-3, SCF, and EPO) were increased. This is in accordance with reports of episodes of leukocytosis and leukemoid reactions with white cell counts greater than 35,000/µL and a left shift of myeloid cells in infants with TAR syndrome.2–3 These reactions could be caused by elevated levels of other hematopoietic growth factors. In fact, we found elevated levels of IL-11 in at least three out of five patients affected with the TAR syndrome. IL-11 is a cytokine that is reported to promote the growth of myeloid and erythroid precursors.34 However, elevation of this cytokine also could have occurred independent of thrombocytopenia seen in these patients.

Platelet functions were reported to be normal in patients with TAR syndrome,3 although few patients had abnormal platelet aggregation and storage pool defects.8,9 Because of the high blood
volume required in testing platelet aggregation in thrombocytopenic patients. We only measured the expression of the activation-dependent antigen CD62P on platelets after stimulation with ADP or TRAP. Under these experimental conditions, we found normal platelet activation in all TAR patients tested.

We examined the in vitro reactivity of platelets to TPO. Although TPO by itself does not cause an increase in α-granule secretion as assayed by CD62P expression, it upregulates the response to ADP or thrombin receptor agonists. However, TPO by itself causes significant tyrosine phosphorylations in a number of different proteins in platelets. In contrast, platelets from TAR patients showed no or very little reactivity to TPO. We found no synergism of TPO to the platelet activators ADP and TRAP. Furthermore, there was no (3 of 4) or very weak (1 of 4) additional tyrosine phosphorylation of platelet proteins after stimulation with TPO. From this defective reactivity of platelets in response to TPO, we assume a defect of all cells of the megakaryocytopenesis including megakaryocyte progenitor cells. This defective response might be the cause of thrombocytopenia in the TAR syndrome. Signal transduction pathways downstream of c-Mpl should be essentially similar in platelets and their progenitors in the bone marrow. Regardless of whether the signal transduction in platelets is a simple remnant from the megakaryocytes or whether there is a physiological role of TPO in platelet activation. Miyakawa et al. showed phosphorylation of the signal transduction molecules Jak2, Shc, Stat3, and Stat5 in platelets in response to TPO. These data correspond to those obtained with cell lines normally expressing or engineered to express c-Mpl. We could show that c-Mpl is expressed on the surface of platelets in TAR patients in similar amounts as in healthy controls. In addition, the molecular weight of the receptor corresponds to that of normal donors. However, point mutations in c-Mpl of TAR patients cannot be excluded as a cause for the defect in signal transduction. This scenario resembles very much the situation in congenital neutropenia patients in which we could show elevated G-CSF serum levels and normal G-CSF receptor expression but defective response to G-CSF in vitro and in vivo. Nevertheless, congenital neutropenia patients responded well to pharmacological dosages of G-CSF with an increase of neutrophils associated with a reduction of bacterial infections, suggesting that treatment of TAR patients with rhTPO might help to increase platelet numbers and improve clinical problems associated with thrombocytopenia.

ACKNOWLEDGMENT

We thank the following physicians for providing us with samples from their TAR patients: Dr H. Habenicht (Hamburg, Germany), Dr H. Jakobi, Dr H.-P. Haastert (Celle, Germany), Dr R. Burghard (Memmingen, Germany), Dr H. Schmidt, Dr U. Richter (Detmold, Germany), and Dr E. Koscielnak (Stuttgart, Germany). In addition, we are grateful to Dr Michael Martin, Department of Molecular
Phannaco(ogy. MHH. for performing the IL-6 and IL-1 ELISAs and Dr Muhan Huang for perfomning the LIF ELISA.

REFERENCES


6. Kanz L, Kostielniak 13, Welte K: Colony-.stimulating activitv (CSA) unique for the megakaryncytic hetnopoietic cell lineage, pres ent in the plasma of a patient with the syndrome of thromhucytopenia with absent radiii (TAR). Blond 74:248a, 1989 (suppl 1. ahstr)


8. Day J. Hulmsen H: Platelet adenine nueleotide „storage pool defleienev” in thromhoeytopenie absent rudi syndrome. JAMA

221:1053, 1972


Stimulation of megakaryoeytopoiesis and thrombopoiesis by the c Mpl ligand. Nature 369:533. 1994

11. Lok 5, Kau5haf15ky K, HolIy RD, Kuijper JL, Lofton-Day


Mar V. MeNineh J, Simonet L, Jacobsen F, Xie C. Shutter J. Chute

H. Basu R. Selander L, Trollinger D, Sieu L. Pudi0u D. Trail G.

Elliott G. Izum R, Covey T, Crouse J, Garcia A, Xu W. Del Castillo


D. Yung YP. Lin H, Bosselman RA: Identification and donine of

mu megakaryocyte growth and development tuetor that is u ligand for

the cytokine receptor Mpl. Cell 77:1117, 1994


86:419,1995


1995


26. Vussalb RRJ. Kieber-Emmons T, Cichowski K. Brass LF:


serotonin, vasopressin or enilagen in a manner independent of thromboxane production. Blood 87:21u, 1995 (suppt, ahstr>  

